Trial register facet
Phase 3 trial records — page 5
351 records at phase 3.
Showing 0 records on this page
Records
351 documents · page 5 of 15
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| MMPOWER-3 | SS-31 (elamipretide) | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 218 | 2022 | Moderate |
| SURMOUNT-1-OLEprogramme record | Tirzepatide | Phase 3 | Reported | Single-arm open-label | — | 2022 | Very low |
| MMPOWER-3-OLEprogramme record | SS-31 (elamipretide) | Phase 3 | Reported | Single-arm open-label | — | 2022 | Very low |
| CELIAC-PH3-CEDLARA-BODY-COMPprogramme record | Larazotide acetate | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2022 | Very low |
| SURMOUNT-1-ELDERLYprogramme record | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2022 | Very low |
| CELIAC-PH3-CEDLARA-REGIONAL-JPprogramme record | Larazotide acetate | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2022 | Very low |
| MMPOWER-3-BIOMARKERprogramme record | SS-31 (elamipretide) | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2022 | Very low |
| MMPOWER-3-ADHERENCEprogramme record | SS-31 (elamipretide) | Phase 3 | Reported | Observational | — | 2022 | Very low |
| STEP-8-BIOMARKERprogramme record | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2022 | Very low |
| STEP-1 | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 1,961 | 2021 | High |
| STEP-2 | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 1,210 | 2021 | High |
| STEP-3 | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 611 | 2021 | High |
| STEP-4 | Semaglutide | Phase 3 | Reported | Randomised withdrawal | 803 | 2021 | High |
| SURPASS-1 | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 478 | 2021 | High |
| SURPASS-2 | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, active-controlled | 1,879 | 2021 | High |
| SURPASS-3 | Tirzepatide | Phase 3 | Reported | Randomised, open-label, active-controlled | 1,444 | 2021 | High |
| SURPASS-4 | Tirzepatide | Phase 3 | Reported | Randomised, open-label, active-controlled | 2,002 | 2021 | High |
| AMPLITUDE-O | Exenatide | Phase 3 | Reported | Event-driven cardiovascular outcome trial | 4,076 | 2021 | Moderate |
| STEP-1-ADHERENCEprogramme record | Semaglutide | Phase 3 | Reported | Observational | — | 2021 | Very low |
| STEP-3-ELDERLYprogramme record | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2021 | Very low |
| SURPASS-2-ELDERLYprogramme record | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2021 | Very low |
| AMPLITUDE-O-REGIONAL-JPprogramme record | Exenatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2021 | Very low |
| STEP-1-BIOMARKERprogramme record | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2021 | Very low |
| STEP-3-OLEprogramme record | Semaglutide | Phase 3 | Reported | Single-arm open-label | — | 2021 | Very low |
page 5 of 15